Qlife Holding AB, Interim Report January – March 2020
Expansion with molecular test on the Egoo systemFINANCIAL SUMMARY FIRST QUARTER 2020 · Revenue for the period amounted to kSEK 385 (0) and regards a collaboration project with a Danish hospital. · EBITDA for the period amounted to kSEK -5,732 (-1,875), and net profit amounted to kSEK -8,704 (-1,893). · Qlife issued 4,472,600 units (4,472,600 shares and 4,472,600 warrants series TO1) through a new share issue in February 2020. Equity capital increased with kSEK 48,950 after issuance costs of kSEK 6,063, and net cash flow from the IPO amounted to kSEK 44,450 after netting of loans